Abrocitinib

Overview

Abrocitinib is an oral selective inhibitor of Janus kinase 1 (JAK1), approved for the treatment of moderate-to-severe atopic dermatitis. It works by modulating the immune response involved in the pathogenesis of the disease.

API suppliers (2)

Suppliers of Abrocitinib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MAITHRI DRUGS PRIVATE LTD1 active DMF
• MAITHRI DRUGS PRIVATE LTD1 active DMF

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Abrocitinib expires 14 Jan 2036 and exclusivity 14 Jan 2027. Generic API sourcing typically opens up once these lapse.

Therapeutic areas